Indivior (NASDAQ:INDV) Posts Earnings Results, Hits Expectations

Indivior (NASDAQ:INDV) posted its quarterly earnings results on Thursday. The company reported $0.32 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.32, Zacks reports. The business had revenue of $298.00 million during the quarter, compared to analyst estimates of $262.35 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. Indivior updated its FY 2025 guidance to EPS.

Indivior Price Performance

Shares of NASDAQ INDV traded down $0.19 during mid-day trading on Friday, hitting $8.80. The company had a trading volume of 856,146 shares, compared to its average volume of 1,176,966. The company has a market capitalization of $1.21 billion, a PE ratio of -219.57 and a beta of 0.73. Indivior has a 1-year low of $7.33 and a 1-year high of $23.22. The business’s 50-day simple moving average is $11.51 and its 200 day simple moving average is $10.87.

Analysts Set New Price Targets

Several research analysts recently weighed in on INDV shares. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw began coverage on Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Piper Sandler restated an “overweight” rating and set a $16.00 price target (up from $15.00) on shares of Indivior in a research note on Friday, October 25th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.